InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Benwahsauce Free
09/14/23 3:25 PM
Post #5,870
profile icon
OTC_Hussler PremiumMember
09/14/23 10:13 AM
Post #5,869
profile icon
Benwahsauce Free
09/14/23 9:42 AM
Post #5,868
profile icon
OTC_Hussler PremiumMember
09/11/23 4:08 PM
Post #5,867
profile icon
Benwahsauce Free
09/11/23 4:07 PM
Post #5,866
profile icon
OTC_Hussler PremiumMember
09/07/23 3:29 PM
Post #5,865
profile icon
OTC_Hussler PremiumMember
09/01/23 1:48 PM
Post #5,863
profile icon
Benwahsauce Free
08/16/23 6:04 PM
Post #5,862
profile icon
OTC_Hussler PremiumMember
08/16/23 5:53 PM
Post #5,861
profile icon
Benwahsauce Free
08/16/23 3:55 PM
Post #5,860
profile icon
OTC_Hussler PremiumMember
08/07/23 9:35 AM
Post #5,859
profile icon
Benwahsauce Free
04/11/23 9:26 PM
Post #5,857
profile icon
OTC_Hussler PremiumMember
04/11/23 8:48 PM
Post #5,856
profile icon
Benwahsauce Free
04/11/23 7:48 PM
Post #5,855
profile icon
OTC_Hussler PremiumMember
04/11/23 5:36 PM
Post #5,854
profile icon
OTC_Hussler PremiumMember
04/11/23 5:35 PM
Post #5,853
profile icon
Benwahsauce Free
04/11/23 4:51 PM
Post #5,852
profile icon
Benwahsauce Free
04/11/23 4:47 PM
Post #5,851
profile icon
Benwahsauce Free
04/11/23 2:37 AM
Post #5,849
profile icon
OTC_Hussler PremiumMember
04/10/23 10:28 AM
Post #5,848
profile icon
OTC_Hussler PremiumMember
03/29/23 10:41 AM
Post #5,847
profile icon
Benwahsauce Free
03/29/23 10:23 AM
Post #5,846
profile icon
OTC_Hussler PremiumMember
01/04/23 10:30 AM
Post #5,845
profile icon
OTC_Hussler PremiumMember
11/10/22 9:32 PM
Post #5,844
profile icon
Lowhndcpr Free
11/10/22 9:03 AM
Post #5,843
profile icon
Renee PremiumMember
11/08/22 5:13 PM
Post #5,842
profile icon
OTC_Hussler PremiumMember
10/07/22 3:48 PM
Post #5,841
profile icon
Benwahsauce Free
09/22/22 9:14 AM
Post #5,840
profile icon
OTC_Hussler PremiumMember
09/22/22 9:12 AM
Post #5,839
profile icon
Benwahsauce Free
09/22/22 8:53 AM
Post #5,838
profile icon
OTC_Hussler PremiumMember
09/22/22 5:25 AM
Post #5,837
profile icon
Benwahsauce Free
09/21/22 4:45 PM
Post #5,836
profile icon
Lowhndcpr Free
09/21/22 2:48 PM
Post #5,835
profile icon
OTC_Hussler PremiumMember
09/12/22 4:41 PM
Post #5,834
profile icon
OTC_Hussler PremiumMember
08/01/22 11:46 AM
Post #5,833
profile icon
Lowhndcpr Free
07/29/22 4:01 PM
Post #5,832
profile icon
Benwahsauce Free
07/22/22 11:37 PM
Post #5,830
profile icon
OTC_Hussler PremiumMember
07/21/22 9:13 PM
Post #5,829
profile icon
Benwahsauce Free
07/21/22 4:41 PM
Post #5,828
profile icon
OTC_Hussler PremiumMember
07/21/22 2:40 PM
Post #5,827
profile icon
Benwahsauce Free
07/21/22 12:44 PM
Post #5,826
profile icon
Golf4Food Free
07/21/22 11:33 AM
Post #5,825
profile icon
OTC_Hussler PremiumMember
07/11/22 10:45 AM
Post #5,824
profile icon
Benwahsauce Free
07/07/22 1:04 PM
Post #5,823
profile icon
Benwahsauce Free
07/05/22 10:46 AM
Post #5,822
profile icon
OTC_Hussler PremiumMember
06/30/22 3:28 PM
Post #5,821

EOM Pharmaceutical Holdings Inc. (IMUC)

Followers
179
Posters
565
Posts (Today)
0
Posts (Total)
5870
Created
10/10/08
Type
Free
Moderators

https://www.imuc.com/

About IMMUNOCELLULAR THERAPEUTICS LTD
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which
 engages in the development of immune-based therapies for the treatment
 of cancers. The company's lead product candidate, ICT-107, is a 
dendritic cell-based immunotherapy targeting multiple tumor-associated
 antigens on glioblastoma stem cells. Its pipeline also includes ICT-
121, a patient-specific, dendritic cell-based immunotherapy targeting
 the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
 patient-specific, dendritic cell-based immunotherapy targeting antigens
 on ovarian cancer stem cells; and the Stem-to-T-cell research program
 which engineers the patient's hematopoietic stem cells to generate
 antigen-specific cancer-killing T cells. The company was founded on
 January 30, 2006 and is headquartered in Los Angeles, CA.

Contacts:

For EOM Pharmaceuticals, Inc:
INVESTOR CONTACT: Wayne I. Danson
Chief Financial Officer & Treasurer
EOM Pharmaceuticals, Inc.

wayned@eompharma.com  
516.384.9757

MEDIA CONTACT: Taylor Mason-Little
TogoRun

t.mason-little@togorun.com
714.466.0301

For ImmunoCellular Therapeutics, Inc:
Jane M. Green
jane@jmgcomm.com
267.457.3734 office
415.652.4819 mobile

SOURCE EOM Pharmaceuticals, Inc.

IMUC SHARE STRUCTURE
  Authorized Shares: 500,000,000 12/31/2021
                                  50,000,000 12/31/2020
Outstanding Shares:   113,270,751  01/05/2022
                                49,270,751 12/03/2021
                                     4,195,213  12/31/2020
          Held at DTC:    4,192,547 12/03/2021
https://www.otcmarkets.com/stock/IMUC/security
Links to see recent MM short volume sales & short interest activity
https://iborrowdesk.com/report/IMUC 15min update
https://marketwirenews.com/stock/imuc/short/ trading + cover days + charts
https://whalewisdom.com/stock/imuc#short_positions 30min updated
http://shortvolumes.com/?t=imuc daily intraday
https://fintel.io/ss/us/imuc bi-monthly + daily intraday
https://shortsqueeze.com/?symbol=imuc&submit=Short+Quote%E2%84%A2 bi-monthly
https://otce.finra.org/otce/equityShortInterest bi-monthly

Recent News
Proposed Reverse Merger EOM & IMUC December 2, 2021
https://www.otcmarkets.com/stock/IMUC/news/EOM-Pharmaceuticals-Inc-And-Immunocellular-Therapeutics-Ltd-Announce-Entry-Into-And-Close-Of-Definitive-Merger-Agreement?id=333764


https://www.eompharma.com/

About EOM Pharmaceuticals
EOM Pharmaceuticals is a clinical-stage company focused on developing
 drugs with the potential to transform therapeutic paradigms and improve
 quality of life in patients suffering from debilitating and sometimes
 deadly diseases, including infectious diseases such as COVID-19; autoimmune
 diseases including rheumatoid arthritis; cachexia associated with AIDS
 and cancer; and retinal diseases. For more information about EOM
 Pharmaceuticals, please visit www.eompharma.com.


weekly

8-34 Daily 180d

Daily 90d
Most Liked Posts
(Last 30 Days)